> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS’ Reblozyl Meets Endpoint in Anemia Patients
- URL: https://www.fdaweb.com/bms-reblozyl-meets-endpoint-in-anemia-patients/
- Published: 2022-10-31T12:00:00.000Z
- Updated: 2026-09-14T18:04:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153086

Bristol Myers Squibb (BMS) has reported that its COMMANDS Phase 3 study evaluating Reblozyl (luspatercept-aamt) met its primary endpoint in first-line treatment of anemia in adult patients with myelodysplastic syndromes who require red blood cell transfusions. The endpoint was the significant and clinically meaningful improvement in red blood cell transfusion independence with concurrent hemoglobin increase, according to the company.

The drug is currently approved for treating anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, and anemia in certain myelodysplastic syndrome patients that did not respond to an erythropoiesis stimulating agent and a blood transfusion was required.

BMS says it will present detailed results at an upcoming medical meeting and discuss the results with health authorities.